Skip to main content
Premium Trial:

Request an Annual Quote

Lion Bioscience Posts Lower Revenues, Net Loss in Q1

NEW YORK, Aug. 5 (GenomeWeb News) - Lion Bioscience today reported lower first-quarter revenues for its fiscal year 2004/2005, but also lowered its net loss for the period.

 

Lion posted revenues of €4 million ($4.81 million) in the quarter ended June 30, 2004, compared to revenues of €5.5 million for the first quarter of fiscal year 2003/2004. According to the bioinformatics firm, 53 percent of its first-quarter revenues were derived from collaborative projects with Bayer.

 

The company reduced its net loss for the quarter to €2.6 million ($3.13 million) from €4.5 million in the comparable period a year ago. Its costs and expenses for the quarter declined 32 percent to €6.3 million ($7.58 million).

 

Lion said it received three new orders for its SRS software and a new cheminformatics professional services order in North America during the quarter.

 

The Heidelberg, Germany-based firm confirmed its forecast for the current fiscal year, with revenues expected to be €12 million-€13 million and its net loss to be €10 million-€11 million.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.